LUKB Actively Managed Tracker Certificate on BLKB Demography Basket

Corporate Action	**Please notice that the terms and conditions of this Product have been adjusted due to a Corporate Action**

These Products are derivative financial instruments and do not qualify as units of a collective investment scheme according to the relevant provisions of the Swiss Federal Act on Collective Investment Schemes ("CISA") and are not registered thereunder. Therefore, the products are not subject to authorisation or supervision by the Swiss Financial Market Supervisory Authority FINMA ("FINMA"). Accordingly, Investors do not have the benefit of the specific investor protection provided under the CISA. Investors bear the Issuer Risk.

Capitalized terms used in this Document shall have the meaning assigned to them in the Base Prospectus.

Summary

Note to Investors	This Summary is an introduction to the final terms (the "Final Terms" or "this Document") for the financial instruments referred in this Document (the "Products") and must be read together with the Base Prospectus. Any investment decision in relation to the Product should not be made based only on this Summary but on the information contained in the Base Prospectus and these Final Terms. Investors should, in particular, read the section "Risk Factors" in the Base Prospectus and the section "3. Significant Risks for the Investors" in this Document. **Any liability for information contained in this Summary is limited to cases where the information contained herein is misleading, inaccurate or inconsistent when read together with the Base Prospectus and the other parts of Final Terms.**
Issuer	Luzerner Kantonalbank AG (Rating: Standard & Poor's AA)
Investment Advisor	Basellandschaftliche Kantonalbank
Product Type	LUKB Actively Managed Tracker Certificate
SSPA Product Category / Type	Participation / Tracker Certificate (1300), according to the Swiss Derivative Map provided by the Swiss Structured Products Association
Underlying	BLKB Demography Basket
Underlying composition	Dynamic and discretionary
Valor / ISIN / SIX Symbol	110435293 / CH1104352930 / DEMOLK
Issue Price	CHF 1,000.00 (100.00% of the Initial Basket Level)
Initial Basket Level	CHF 1,000.00
Management Style	Certificate Style: secondary market activities in the Product do not change the weighting of any Basket Component.
Income treatment	Cash compensation equal to the sum of the proportional net dividends, net coupons resp. net distributions paid by Basket Components

Minimum Investment Amount / Minimum Trading Lot	1 Product or a multiple thereof
Product Currency	CHF
Settlement Type	Cash
Initial Fixing Date / Issue Date	15.06.2021 / 22.06.2021
Maturity	Open End
Offering	Public offer in Switzerland
Listing	Application to list and admit to trading on the SIX Swiss Exchange will be made.
Quoting	Accrued Compensation Payment Amount is included in the price ("dirty") / in units
Selling Restrictions	No action has been taken by the Issuer to permit a public offering of these Products in any jurisdiction other than Switzerland. (for more details see section "Selling Restriction" under "1. Product Description - Information about the Offer" of these Final Terms below and "2. Selling Restrictions" of the Base Prospectus)
Total Expense Ratio (TER)	1.00% p.a.
Market Expectation / Payoff	Rising / Participating

1. Product Description

LUKB Actively Managed Tracker Certificates offer Investors the opportunity to replicate the price movement of the Basket and thus to participate in its development. The risk/return profile of this Product is comparable to the risk/return profile of the Basket. The Basket consists of several components (the «Basket Components») and represents the Underlying of this Product. The Basket is **dynamic** and managed **discretionary** by the Investment Advisor during the lifetime of the Product. The Investment Advisor composes the Basket in line with the Investment Strategy at his own discretion and can amend the composition at any time. Thus, the performance of the Basket depends on the Investment Strategy pursued by the Investment Advisor and its implementation. This Product provides variable annual payments as compensation for the sum of the proportional net dividends, net coupons resp. net distributions paid by the Basket Components.

OPERATIONAL INFORMATION

SSPA Product Category / Type	**Participation** / Tracker Certificate (1300), according to the Swiss Derivative Map provided by the Swiss Structured Products Association
Valor / ISIN / SIX Symbol	110435293 / CH1104352930 / DEMOLK
Listing	Will be applied for on the SIX Swiss Exchange, First Trading Day: 22.06.2021 (anticipated)
Recognized Representative (Art. 43 resp. Art. 58a Listing Rules)	Luzerner Kantonalbank AG, Lucerne, Switzerland
Secondary Market Trading	The Issuer intends to make a market in these Products on a regular basis under normal market conditions and as long as there is sufficient liquidity in the Basket Components. The execution of secondary market orders may be delayed due to limited liquidity in the Basket Components. Price indications are available under **structuredproducts.lukb.ch**, Refinitiv [ISIN]=LUKB and Bloomberg [ISIN] Corp.

PRODUCT TERMS AND CONDITIONS

Issuer / Lead Manager / Paying and Calculation Agent	Luzerner Kantonalbank AG, Lucerne, Switzerland Rating: Standard & Poor's AA Supervisory Authority: FINMA
Investment Advisor	Basellandschaftliche Kantonalbank, Liestal, Switzerland Supervisory Authority: FINMA
Investment Strategy	The BLKB Demography Basket contains small, mid and large caps worldwide (all markets). BLKB checks whether there are companies among the titles in the universe that are affected by the BLKB sustainability exclusion criteria. These companies are excluded from the universe. This is followed by a best-in-class filtering of the companies according to ESG rating (ESG: environment, social and corporate governance) as well as a selection of solution providers in the area of demographic change resp. in the context of an aging society. Finally, a credit risk filter is applied. The Investment Advisor provides for a quarterly rebalancing (February, May, August, November), but reserves the right to rebalance also on an ad hoc basis. The Investment Strategy does not involve leverage and is implemented in accordance with the Investment Guidelines. These guidelines provide for a maximum investment degree of 100% and a weighting of the individual basket components between a minimum of 0% and a maximum of 100%. The basket contains a cash position. Further information on the Investment Strategy, the Investment Guidelines and the Investment Restrictions - if available - can be obtained free of charge from the Issuer: Luzerner Kantonalbank AG Structured Products, Pilatusstrasse 12, 6003 Lucerne, Email: **structuredproducts@lukb.ch**.
Underlying Universe	The relevant universe of securities consists of small, mid and large caps worldwide (all markets). BLKB checks whether there are companies among the titles in the universe that are affected by the BLKB sustainability exclusion criteria. These companies are excluded from the universe. The BLKB exclusion criteria with regard to sustainability include, for example, climate change (promotion of fossil fuels, operation of fossil power plants, production of aircraft / airlines, etc.), damage to health (tobacco, gambling, nuclear energy, etc.), ethics (weapons, adult entertainment, etc.) and decline in biodiversity (genetically modified seeds, etc.). The BLKB sustainability criteria are continuously checked and adjusted if necessary. Equity securities such as shares, participation certificates and profit-sharing certificates that are listed or admitted to trading on SIX Swiss Exchange or on a foreign securities exchange with equivalent regulation are permitted as underlying instruments. The underlyings are selected by the Investment Advisor as part of the Investment Strategy implementation. In addition to the above underlyings, a Cash Position is used as a Basket Component and is included in the Basket. The Cash Position is in the currency of the product. The Cash Position does not bear interest, however the Issuer reserves the right to charge negative interest rates in the future. The share of the Cash Position may not exceed 10% of the product value.

Implementation of the Investment Strategy	The Investment Advisor is solely responsible for the implementation and compliance of the Investment Strategy and decides solely on the composition and reallocation (rebalancing) of the Basket. The Issuer has no obligation to monitor this, but reserves the right to refuse to accept a new Basket Component by the Investment Advisor without giving any reasons.
Minimum Investment Amount / Minimum Trading Lot	1 Product or a multiple thereof
Number of Products	20,000 Products (with the option to increase)
Product Currency	CHF
Compensation Payment Amounts / Payment Decision Dates / Payment Dates	Each Product gives the Investor the right to receive on the Payment Dates the Compensation Payment Amounts: Compensation Payment Amounts: The sum of the proportional net dividend payments, net coupon payments resp. net distributions received by the Issuer in relation to any of the Basket Components, converted on the receive date into the Product Currency, if applicable. The first Compensation Payment Amount, provided that any such dividend payment, coupon payment resp. distribution is received by the Issuer between the Initial Fixing Date (excluding) and the first Payment Decision Date (including), will be paid on the first Payment Date. The following Compensation Payment Amounts, provided that any such dividend payment, coupon payment resp. distribution is received between a Payment Decision Date (excluding) and the next Payment Decision Date (including) will be paid on the following Payment Dates. Annual Payment Decision Date: 31.05. (modified following) Annual Payment Date: 07.06. (modified following) Section 5.1.15 of the General Terms and Conditions of the Base Prospectus applies mutatis mutandis to Compensation Payment Amounts.
Basket Level	With reference to the relevant day, the sum of the multiplications of the respective number of Basket Components with the relevant price of each Basket Component, if applicable converted into the Product Currency.
Redemption Amount	The Redemption Amount per Actively Managed Tracker Certificate on the Termination Date corresponds to the Basket Level on the Termination Date, or is determined by the Calculation Agent on a best effort basis, based on the net sale prices of the Basket Components during the fixing period, plus the accrued compensation payments and less the accrued fees. The fixing period is at the discretion of the Issuer and is primarily based on the liquidity of the Basket Components; if one or more Basket Components have limited liquidity, the fixing period can be extended.
Initial Basket Level	CHF 1,000.00 The Initial Basket Level corresponds to the sum of the multiplications of the respective number of Basket Components on the Initial Fixing Date with the Initial Fixing Level of each Basket Component, if applicable converted into the Product Currency, as determined by the Calculation.

Initial Fixing Date	15.06.2021
Issue Date	22.06.2021
Maturity	Open End (Product with no fixed maturity)
Initial Fixing Level	The relevant price of the respective Basket Component and respective foreign exchange rate will be reasonably determined by the Calculation Agent on the Initial Fixing Date. Local taxes, transactions fees and foreign commissions, if applicable, are also reflected in the Initial Fixing Level of each Basket Component and are thus borne by the Investors in this Product.
Settlement Type	Cash
Annual Fee	The Annual Fee of 1.00% p.a. will be charged daily based on the Product value. The Annual Fee is split in 0.25% p.a. for the Issuer and 0.75% p.a. for the Investment Advisor.
Rebalancing Fee	With each Rebalancing in the Basket (buy and/or sell), a fee of 0.10% on the traded transaction value is charged. The Rebalancing Fee will remain with the Issuer.
Depository	SIX SIS AG
Clearing / Settlement	SIX SIS AG / Euroclear / Clearstream
Underlying	BLKB Demography Basket

Composition of the Underlying resp. Basket (current status on the creation date of the Final Terms):

Basket Component ISIN	Bloomberg Ticker Reference Exchange	Initial Fixing Level Reference Currency	Weighting	Number of Basket Components
Abbott Laboratories **US0028241000**	ABT UN Equity NYSE	USD 102.6500 USD	2.0000%	0.168468
Aflac Inc **US0010551028**	AFL UN Equity NYSE	USD 59.4200 USD	2.0000%	0.250100
AIA Group Ltd **HK0000069689**	1299 HK Equity Hong Kong	HKD 94.4030 HKD	1.9998%	1.919566
AMEDISYS Inc **US0234361089**	AMED UW Equity Nasdaq	USD 249.9236 USD	2.0000%	0.196819
Ameriprise Financial Inc **US03076C1062**	AMP UN Equity NYSE	USD 274.8551 USD	2.0000%	0.054504
Baxter International Inc. **US0718131099**	BAX UN Equity NYSE	USD 84.6500 USD	2.0000%	0.321704
Bio-Techne Corp **US09073M1045**	TECH UW Equity Nasdaq	USD 82.9525 USD	2.0000%	0.214944

Basket Component ISIN	Bloomberg Ticker Reference Exchange	Initial Fixing Level Reference Currency	Weighting	Number of Basket Components
Boston Scientific Corp **US1011371077**	BSX UN Equity NYSE	USD 40.3100 USD	2.0000%	0.405460
Challenger Ltd **AU000000CGF5**	CGF AT Equity ASX	AUD 6.8900 AUD	2.0003%	3.670027
Coloplast A/S **DK0060448595**	COLOB DC Equity Copenhagen	DKK 995.9320 DKK	1.9999%	0.144871
CVS Health Corp. **US1266501006**	CVS UN Equity NYSE	USD 98.1500 USD	2.0000%	0.176826
Dai-ichi Life Holdings,Inc. **JP3476480003**	8750 JT Equity Tokyo Stock Exchange	JPY 2,166.4446 JPY	2.0003%	0.994089
Danaher Corp. **US2358511028**	DHR UN Equity NYSE	USD 269.9100 USD	2.0000%	0.067983
Dexcom Inc. **US2521311074**	DXCM UW Equity Nasdaq	USD 101.6223 USD	2.0001%	0.157729
Edwards Lifesciences Corp **US28176E1082**	EW UN Equity NYSE	USD 100.3466 USD	2.0000%	0.234298
Eli Lilly & Co. **US5324571083**	LLY UN Equity NYSE	USD 361.5881 USD	2.0001%	0.048543
Equitable Holdings Inc **US29452E1010**	EQH UN Equity NYSE	USD 30.2250 USD	2.0000%	0.579839
Exact Sciences **US30063P1057**	EXAS UQ Equity Nasdaq	USD 35.5500 USD	1.9999%	0.427813
Great-West Lifeco Inc **CA39138C1068**	GWO CT Equity Toronto Stock Exchange	CAD 37.4248 CAD	1.9999%	0.751268
Healthpeak Properties Inc **US42250P1030**	PEAK UN Equity NYSE	USD 34.9325 USD	2.0000%	0.715328
Hologic Inc **US4364401012**	HOLX UQ Equity Nasdaq	USD 71.1100 USD	2.0000%	0.240418
Humana Inc **US4448591028**	HUM UN Equity NYSE	USD 420.5889 USD	2.0000%	0.033231
Johnson & Johnson **US4781601046**	JNJ UN Equity NYSE	USD 164.9313 USD	2.0001%	0.100126
Laboratory Corp Of America Holdings **US50540R4092**	LH UN Equity NYSE	USD 260.9618 USD	2.0000%	0.074488

Basket Component ISIN	Bloomberg Ticker Reference Exchange	Initial Fixing Level Reference Currency	Weighting	Number of Basket Components
Legal & General Group PLC **GB0005603997**	LGEN LN Equity London Stock Exchange	GBP 2.5846 GBP	2.0000%	5.750753
LHC Group Inc **US50187A1079**	LHCG UW Equity Nasdaq	USD 202.1759 USD	2.0001%	0.105812
Manulife Financial Corp **CA56501R1064**	MFC CT Equity Toronto Stock Exchange	CAD 24.1919 CAD	1.9999%	1.010827
Medacta Group AG **CH0468525222**	MOVE SE Equity SIX Swiss Exchange	CHF 101.0864 CHF	2.0000%	0.161048
Medibank Private Ltd **AU000000MPL3**	MPL AT Equity ASX	AUD 3.1028 AUD	2.0004%	9.194466
Medtronic PLC **IE00BTN1Y115**	MDT UN Equity NYSE	USD 76.5727 USD	1.9998%	0.233192
Merit Medical Systems Inc **US5898891040**	MMSI UW Equity Nasdaq	USD 68.7315 USD	2.0000%	0.253058
Mirati Therapeutics Inc **US60468T1051**	MRTX UW Equity Nasdaq	USD 81.0300 USD	1.9999%	0.185574
Molina Healthcare Inc **US60855R1005**	MOH UN Equity NYSE	USD 337.3700 USD	2.0001%	0.054376
NN Group N.V. **NL0010773842**	NN NA Equity Euronext Amsterdam	EUR 41.0397 EUR	2.0000%	0.422175
Novo Nordisk A/S -B- **DK0060534915**	NOVOB DC Equity Copenhagen	DKK 519.2015 DKK	1.9998%	0.148108
Phoenix Group Holdings PLC **GB00BGXQNP29**	PHNX LN Equity London Stock Exchange	GBP 7.2868 GBP	2.0000%	2.443274
Primerica Inc **US74164M1080**	PRI UN Equity NYSE	USD 126.7500 USD	2.0000%	0.122669
Principal Financial Group Inc **US74251V1026**	PFG UW Equity Nasdaq	USD 74.7600 USD	1.9999%	0.198276
Quest Diagnostics Inc **US74834L1008**	DGX UN Equity NYSE	USD 128.1046 USD	2.0001%	0.119108
R1 RCM Inc **US77634L1052**	RCM UW Equity Nasdaq	USD 22.1847 USD	1.9998%	2.363918

Basket Component ISIN	Bloomberg Ticker Reference Exchange	Initial Fixing Level Reference Currency	Weighting	Number of Basket Components
Roche Holding AG CH0012032048	ROG SE Equity SIX Swiss Exchange	CHF 343.6500 CHF	1.9999%	0.053817
Shanghai Fosun Pharmaceutical (Group) Co Ltd CNE100001M79	2196 HK Equity Hong Kong	HKD 24.8686 HKD	2.0000%	5.711805
ShockWave Medical Inc US82489T1043	SWAV UW Equity Nasdaq	USD 188.4740 USD	2.0000%	0.069010
Storebrand ASA NO0003053605	STB NO Equity Oslo	NOK 81.2419 NOK	1.9999%	2.047145
Swiss Life Holding AG CH0014852781	SLHN SE Equity SIX Swiss Exchange	CHF 461.4000 CHF	2.0000%	0.033520
SYNLAB AG DE000A2TSL71	SYAB GY Equity Xetra	EUR 14.5152 EUR	2.0000%	1.256315
T&D Holdings Inc JP3539220008	8795 JT Equity Tokyo Stock Exchange	JPY 1,451.6682 JPY	2.0003%	1.520280
UnitedHealth Group Inc. US91324P1021	UNH UN Equity NYSE	USD 519.3300 USD	2.0000%	0.033357
Ventas Inc US92276F1003	VTR UN Equity NYSE	USD 52.0000 USD	1.9999%	0.401856
Welltower Inc US95040Q1040	WELL UN Equity NYSE	USD 81.7978 USD	1.9998%	0.266394

For additional information relating to the Underlyings resp. Basket, please refer to "Annex for Additional Information relating to the Underlyings".

Current composition of the Basket

The current composition of the Basket can be obtained from the Issuer at any time or can be found on the Issuer's website at **structuredproducts.lukb.ch**.

Issuer Call

The Issuer has the right to terminate all outstanding Products for the purpose of early redemption without giving any reason on a annually basis on June 22 (modified following, for the first time in June 2022) ("Termination Date"). For further information on the Issuer Call, please refer to Section 5.1.13 of the General Terms and Conditions of the Base Prospectus.

Extraordinary right of termination of the Issuer

If changes in the Basket are planned or have already been made, which, in the sole opinion of the Issuer, are such that a continuation of the Products does not appear appropriate, the Issuer has the right to terminate at any time all outstanding Products for the purpose of early redemption without giving any reason on a freely determined Termination Date.

The corresponding notification must be published as soon as possible, stating the Termination Date.

Investor Put	Subject to prior notice by the Issuer, each Investor has the right to terminate its Products on a annually basis on June 22 (modified following, for the first time in June 2022) ("Termination Date"). The Investor must provide the Paying Agent with a duly completed and signed termination notice (with the information in accordance with section 5.1.13 ii. b. of the General Terms and Conditions of the Base Prospectus) no later than 10 bank working days before the Termination Date by letter mail or by email (Luzerner Kantonalbank AG Structured Products, Pilatusstrasse 12 , 6003 Luzern, **structuredproducts@lukb.ch**). By submitting the termination notice, the Investor undertakes not to transfer the terminated Products. If the Investor has deposited the Products at a third bank (custodian bank), he must also inform them in good time about the exercise of the termination.
Redemption at Termination Date	The Redemption Amount is determined by the Calculation Agent on the Termination Date. The Redemption is made 5 bank working days after the Termination Date. The Issuer may extend the determination of the Redemption Amount to several days at its sole discretion if it considers this necessary due to current market conditions (such as liquidity in the Basket Components). The corresponding notification must be published at least 10 bank working days in advance. The Redemption will then be made 5 bank business days after the calculation of the Redemption Amount by the Calculation Agent.
Notices / Adjustments	The Terms and Conditions of this Product may be subject to Adjustments over the lifetime of this Product (e.g. due to Corporate Actions). Notices with respect to Adjustments and all other notices to Investors shall be made on the website of the Issuer at **structuredproducts.lukb.ch/services/notices** or any successor website. With the valor search function (Valorensuchfunktion) such Products can be located. If this Product is listed on an Exchange, the notices will be published in accordance with the rules issued by the relevant Exchange on the relevant Exchange website.
Market Disruption Event	If the Issuer and/or the Calculation Agent determines, in its reasonable discretion, that a day relevant for the determination of the price of one or some of the components of the Underlying (each an "Affected Component") is a Disrupted Day then the Issuer and/or the Calculation Agent shall determine the relevant price of the Affected Component in its reasonable discretion taking into account established market practice, including, but not limited to, using the most recently traded price or a fair value established at its sole discretion. "Disrupted Day" means any Business Day on which any relevant exchange fails to open for trading during its regular trading session or on which an event has occurred that disrupts or impairs (as determined by the Issuer and/or Calculation Agent) the ability of market participants to effect transactions in or obtain market prices for, any components of the Underlying.
Form	Dematerialised uncertificated securities in accordance with article 973c of the Swiss Code of Obligations transformed into intermediated securities in accordance with article 6 of the Swiss Federal Intermediated Securities Act.
Applicable Law / Place of Jurisdiction	**Swiss law / Lucerne, Switzerland**

INFORMATION ABOUT THE OFFER

Offering	Public offer in Switzerland
Issue Price	CHF 1,000.00 (100.00% of the Initial Basket Level)
IEV / TER / Distribution Fee	Issuer Estimated Value (IEV): CHF 1,000.00 Total Expense Ratio (TER): 1.00% p.a. This Product does not contain any Distribution Fees.
Quoting	Accrued Compensation Payment Amount is included in the price, **"dirty"**. Secondary market prices are quoted in **units**.
Selling Restrictions	No action has been taken by the Issuer to permit a public offering of these Products in any jurisdiction other than Switzerland. The offering, sale and/or distribution of these Products in certain jurisdictions may be restricted by applicable law. Persons, who obtain possession of the Product Documentation, are required to inform themselves about and to adhere to any such restrictions which are set out in more detail under section 2 headed "Selling Restrictions" in the Base Prospectus. Particular attention should be paid to the selling restrictions set out in the Base Prospectus with respect to the following jurisdictions: European Economic Area (EEA), United States of America and United Kingdom. These restrictions must not be taken as conclusive guidance as to whether the Products can be sold in a jurisdiction. As regards the EEA the below section "Prohibition of Sales to EEA Retail Investors" further specifies the applicable set of rules. The Product Documentation does not constitute, and may not be used for the purposes of, an offer or solicitation by anyone in any jurisdiction in which such offer or solicitation is not authorised or to any person to whom it is unlawful to make such offer or solicitation.
Prohibition of Offer to Private Clients in Switzerland	Not applicable; a key information document required under article 58 para. 1 FinSA in connection with article 59 para. 2 FinSA has been prepared in respect of the Products which is available for download on the website of the Issuer at **structuredproducts.lukb.ch**.
Prohibition of Sales to EEA Retail Investors	Not applicable "Not applicable" means: A key information document required by Regulation (EU) No 1286/2014 (as amended, the "**PRIIPs Regulation**") for offering or selling the Products or otherwise making them available to retail investors in the European Economic Area ("**EEA**") has been prepared. For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended, "**MiFID II**"); (ii) a customer within the meaning of Directive 2016/97/EU (as amended), where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II; or (iii) not a qualified investor as defined in Directive 2003/71/EC (as amended or superseded, the "**Prospectus Directive**").

TAX TREATMENT IN SWITZERLAND

Income Tax (Direkte Bundessteuer)	The following income tax information is only applicable to private investors resident in Switzerland holding the Product as private assets. The Issuer prepares an annual report to the attention of the Federal Tax Administration as of December 31 of each year.This report shows the performance (change from the previous year) divided into the components income and capital gain. As of the reporting date, the income component is subject to income tax. The capital gain component is not subject to income tax.
Swiss Withholding Tax (Schweizerische Verrechnungssteuer)	The Product is not subject to withholding tax.
Securities Turnover Tax (Umsatzabgabe)	Secondary market transactions are not subject to the securities turnover tax.
Automatic Exchange of Information in Tax Matters	Switzerland has implemented the Automatic Exchange of Information in Tax Matters ("AEOI") as of 1st January 2017 with the EU and various other countries and is negotiating the introduction of the AEOI with further countries. The website **www.sif.admin.ch** provides an overview of all partner states Switzerland has signed an agreement for the introduction of the AEOI.
General Information	The information above is a summary of the main Swiss tax consequences in relation to dealings in this Product and should not be construed to be tax advice. This summary does not purport to address all Swiss tax consequences that may be relevant for a decision to purchase, own and dispose of Products and in particular does not take into account the specific circumstances of any particular investor. The relevant tax laws or the regulation and the practice of the Swiss tax authorities (or their interpretation) are subject to change, possibly with retroactive effect. This summary is based on the tax laws, regulations and practices of Switzerland, as in effect on the earlier of the start of the Subscription Period or the Initial Fixing Date. Transactions and payments of this Product may be subject to further (foreign) transaction taxes, duties and/or withholding taxes (such as, inter alia, withholding tax related to FATCA or 871(m) of the US Tax Code). Any payments due under the Product **are net of any such taxes and/or duties.** It should be noted that all taxes and duties incurred in connection with the investment in this Product are to be borne by the Investor.

2. Prospects of Profits and Losses

Market Expectation	Investors in this Product expect an increase of the Basket Components respectively the Basket Level.
Maximum Return	The maximum return is theoretically unlimited.
Maximum Loss	Investors may lose all of the invested capital.

3. Significant Risks for the Investors

Potential Investors should ensure that they have sufficient knowledge to evaluate and understand the risks and benefits of an investment in this Product and to consider the suitability of this Product as an investment in light of their own circumstances, investment objectives, tax position and financial condition by consulting their own professional financial, accounting, legal and tax advisors. Thereafter Potential Investors should consider the additional risk factors in the Base Prospectus.

Issuer Risk	Investors in this Product bear the Issuer Risk. Potential Investors should therefore be aware that they are exposed to the credit risk of the Issuer. Hence, Investors bear the risk that the financial situation of the Issuer could deteriorate and the Issuer of the Product may become insolvent. In this case all forthcoming and thus not yet occurred compensation payments will also be affected by such insolvency and not be paid. The Product's value is therefore not only dependent on the performance of the Underlying(s) but also on the creditworthiness of the Issuer, which may change over the term of the Product. The Issuer Rating stated in this Final Terms may be subject to change.
Loss Potential	This Product provides no minimum repayment amount. Therefore, Potential Investors may lose all of the invested capital.
Capital Protection	This Product does not provide for a capital protection.
Risks compared to a direct Investment in the Underlying(s)	The risk potential is similar to a direct investment in the Underlying in the Basket Components.
Early Termination and Cancellation	Under certain circumstances set forth in the General Terms and Conditions, the Issuer has the right to terminate and cancel this Product early and pay Investors the fair market value of this Product at the effective date of the Early Termination and Cancellation. Hence, Potential Investors should be aware that they may make a loss on their invested capital if the Products are terminated and cancelled early.
Secondary Market	Even though the Issuer intends to make a market in these Products on a regular basis under normal market conditions, the Issuer is under no obligation with respect to Investors to provide any market in this Product at all, whereby any market making provisions of the stock exchange apply with regard to listed products. Potential Investors should note that there is no guarantee of a specific liquidity or a specific spread (difference between bid and ask prices) or any prices at all. Hence, Potential Investors should not rely on the possibility to buy or sell the Product in a specific point in time or to a specific price. By selling the Product in the secondary market Investors may receive less than the invested capital. In case of a secondary market transaction, there is a possibility that costs, including taxes, related to or in connection with this Product may arise for Investors that are not paid by the Issuer or imposed by the Issuer. Any cash amount derived from sales of Products by the Issuer on the secondary market is proportionally invested in all Basket Components. In contrast, repurchases of Products by the Issuer on the secondary market lead to a proportional reduction of all Basket Components. The weightings remain unchanged before and after the sales/purchases.
Market Disruption	Under certain circumstances set forth in the General Terms and Conditions, if the Issuer and/or Calculation Agent determines that a specified Market Disruption

Event has occurred, any consequential adjustments in line with Combined Terms and Conditions may have an adverse effect on the value of this Product.

Volatility	Potential Investors should take into account that market prices for this Product may be volatile, depending upon the development of the price or value of the Underlying(s) resp. Basket, interest rates, remaining term of the Product and other factors.
Implementation of the Investment Strategy	It is possible that the Investment Strategy will not achieve its goal, and the development of the Investment Strategy depends on the Investment Advisor. There is no guarantee that the Investment Advisor will successfully implement the Investment Strategy and that the Investment Strategy will develop positively.

Important Additional Information

No Offer or Advice	These Final Terms shall not be used or considered as an offer, personal recommendation or solicitation to conclude a transaction and should not be treated as giving investment advice.
No Representation	Neither the Issuer nor any third party appointed by the Issuer, make a representation or warranty relating to any information in this Document, which is derived from independent sources.
Issuer Estimated Value ("IEV") / Total Expense Ratio ("TER") / Distribution Fees	IEV and TER are calculated by the Issuer or any third party appointed by the Issuer, as applicable, on the Initial Fixing Date, or at the start of the Subscription Period and will not be updated during the term of the Product. TER corresponds to the difference between the Issue Price of the Product and the IEV and is comprised of the expected issuer margin and the Distribution Fee, if any and contains also the Annual Fee. The Rebalancing Fee is not part of the TER. The Issuer margin covers amongst others the costs for the structuring, market making and settlement of the Product as well as the expected issuer revenues. The Issue Price (including IEV and TER) of the Product is calculated based on internal pricing models of the Issuer. The Issuer may sell this Product to financial intermediaries and other financial institutions at a discount to the Issue Price or reimburse a certain amount of the Issue Price to them ("Distribution Fees"). Distribution Fees, if any, are disclosed in section 1 of this document and reflect the maximum amount a financial intermediary or financial institution may receive from the Issuer; the actual amount may be lower. Detailed information is available on request.
Prudential Supervision of the Issuer	As a bank within the meaning of the Swiss Federal Act on Banks and Saving Banks and a securities firm within the meaning of the Swiss Federal Act on Financial Institutions, Luzerner Kantonalbank AG is subject to the prudential supervision of FINMA, Laupenstrasse 27, CH-3003 Bern, **finma.ch**.
Consent to use the Base Prospectus	General Consent as defined in the Base Prospectus is given by the Issuer.
Legally binding Documentation	The legally binding versions of the Base Prospectus and the relevant Final Terms (together the "Product Documentation") are in German language. Translations in other languages are for information purposes only and are not legally binding. The Products may be publicly offered after the expiry date of the Base Prospectus on the basis of one or more succeeding base prospectuses (each a "Succeeding Base Prospectus"), to the extent the Succeeding Base Prospectus envisages a continuation of the public offer of the Products. In this context, these Final Terms are, in each case, to be read in conjunction with the most recent Succeeding Base Prospectus. The respective Succeeding Base Prospectus will be approved and published prior to the expiry of the validity of the respective preceding base prospectus. **During the entire term of any relevant Product, the Base Prospectus (and any relevant Succeeding Base Prospectus) and the applicable Final Terms can be obtained free of charge from the Issuer under Luzerner Kantonalbank AG Structured Products, Pilatusstrasse 12, 6003 Lucerne, Tel.: +41 44 206 99 55,**

structuredproducts@lukb.ch, structuredproducts.lukb.ch. Calls to this number are recorded. By calling this number, we assume your consent to such recording is given.

Confirmation	As of the date of this Document, there has been no material adverse change, nor any event involving a prospective material adverse change, in the assets and liabilities or financial position of the Issuer since the date of its most recently published financial statements of the Issuer.
Responsibility	The Issuer accepts responsibility for the information contained in the Final Terms. The Issuer states that the information contained in the Final Terms is, to the best of its knowledge, in accordance with facts, correct and does not omit material information, as of the date of this Document.

Annex for Additional Information relating to the Underlyings

Abbott Laboratories
Headquarters: Abbott Park, Illinois, United States
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Abbott Laboratories
Financial Statement: Available under www.abbott.com

Aflac Inc
Headquarters: 1932 Wynnton Rd, COLUMBUS, GA, 31999-0001, United States
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Aflac Inc
Financial Statement: Available under www.aflac.com

AIA Group Ltd
Headquarters: 35/F, AIA Central,No.1 Connaught Road Central, Hong Kong
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of AIA Group Ltd
Financial Statement: Available under www.aia.com.hk

AMEDISYS Inc
Headquarters: 3854 American Way Ste A, BATON ROUGE, LA, 70816-4013, United States
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of AMEDISYS Inc
Financial Statement: Available under www.amedisys.com

Ameriprise Financial Inc
Headquarters: 55 Ameriprise Financial Center, Minneapolis, Minnesota 55474
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Ameriprise Financial Inc
Financial Statement: Available under www.ameriprise.com

Baxter International Inc.
Headquarters: One Baxter Parkway Deerfield, IL 60015 United States
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Baxter International Inc.
Financial Statement: Available under www.baxter.com

Bio-Techne Corp
Headquarters: 614 MCKINLEY PL N E, MINNEAPOLIS, MN, 55413, United States
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Bio-Techne Corp
Financial Statement: Available under www.bio-techne.com

Boston Scientific Corp
Headquarters: 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA, 01752-1234, United States
Form of Shares: Registered shares
Transferability and Limitations: According to the articles of incorporation of Boston Scientific Corp
Financial Statement: Available under www.bostonscientific.com

Challenger Ltd
Headquarters: L 2 5 Martin Place, SYDNEY, NSW, 2000, Australia
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Challenger Ltd
Financial Statement: Available under www.challenger.com.au

Luzerner Kantonalbank BLKB

Coloplast A/S
Headquarters: Holtedam 1-3, HUMLEBAEK, 305, Denmark
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Coloplast A/S
Financial Statement: Available under www.coloplast.com

CVS Health Corp.
Headquarters: Woonsocket, Rhode Island 02895, United States
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of CVS Health Corp.
Financial Statement: Available under www.cvshealth.com

Dai-ichi Life Holdings,Inc.
Headquarters: DN Tower 21, 1-13-1, Yuraku-cho, CHIYODA-KU, TKY, 100-8411, Japan
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Dai-ichi Life Holdings,Inc.
Financial Statement: Available under www.dai-ichi-life.co.jp

Danaher Corp.
Headquarters: 2200 Pennsylvania Avenue, NW, Suite 800W Washington, DC 20037, USA
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Danaher Corp.
Financial Statement: Available under www.danaher.com

Dexcom Inc.
Headquarters: A6340 Sequence Drive, Sand Diego, CA 92121, USA
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Dexcom Inc.
Financial Statement: Available under www.dexcom.com

Edwards Lifesciences Corp
Headquarters: 1 Edwards Way, IRVINE, CA, 92614-5688, United States
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Edwards Lifesciences Corp
Financial Statement: Available under www.edwards.com

Eli Lilly & Co.
Headquarters: Lilly Corporate Center, Indianapolis, IN 46285, United States
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Eli Lilly & Co.
Financial Statement: Available under www.lilly.com

Equitable Holdings Inc
Headquarters: 1290 AVENUE OF THE AMERICAS, NEW YORK, NY, 10104-0101, United States
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Equitable Holdings Inc
Financial Statement: Available under www.equitable.com

Exact Sciences
Headquarters: 5505 Endeavor Lane, MADISON, WI, 53719, United States
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Exact Sciences
Financial Statement: Available under www.exactsciences.com

Great-West Lifeco Inc
Headquarters: PO Box 6000,100 Osborne St. N., Stn Main, WINNIPEG, MB, R3C 3A5, Canada
Form of Shares: Registered Share
Transferability and Limitations: According to the articles of incorporation of Great-West Lifeco Inc
Financial Statement: Available under www.greatwestlifeco.com

Healthpeak Properties Inc
Headquarters: 5050 SOUTH SYRACUSE STREET, SUITE 800, DENVER, CO, 80237, United States
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Healthpeak Properties Inc
Financial Statement: Available under www.healthpeak.com

Hologic Inc
Headquarters: 250 Campus Dr, MARLBOROUGH, MA, 01752-3020, United States
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Hologic Inc
Financial Statement: Available under www.hologic.com

Humana Inc
Headquarters: 500 W Main St, LOUISVILLE, KY, 40202, United States
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Humana Inc
Financial Statement: Available under www.humana.com

Johnson & Johnson
Headquarters:
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Johnson & Johnson
Financial Statement: Available under www.jnj.com

Laboratory Corp Of America Holdings
Headquarters: 358 S MAIN ST, BURLINGTON, NC, 27215-5837, United States
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Laboratory Corp Of America Holdings
Financial Statement: Available under www.labcorp.com

Legal & General Group PLC
Headquarters: 1 Coleman Street, LONDON, EC2R 5AA, United Kingdom
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Legal & General Group PLC
Financial Statement: Available under www.group.legalandgeneral.com

LHC Group Inc
Headquarters: 901 Hugh Wallis Rd S, LAFAYETTE, LA, 70508-2511, United States
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of LHC Group Inc
Financial Statement: Available under www.lhcgroup.com

Manulife Financial Corp
Headquarters: 1-200 Bloor St E, North Tower 10, TORONTO, ON, M4W 1E5, Canada
Form of Shares: Registered Share
Transferability and Limitations: According to the articles of incorporation of Manulife Financial Corp
Financial Statement: Available under www.manulife.com

Medacta Group AG
Headquarters: Strada Regina 34, CASTEL SAN PIETRO, 6874, Switzerland
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Medacta Group AG
Financial Statement: Available under www.medacta.com

Medibank Private Ltd
Headquarters: 720 Bourke Street, Docklands, MELBOURNE, VIC, 3008, Australia
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Medibank Private Ltd
Financial Statement: Available under www.medibank.com.au

Luzerner Kantonalbank BLKB

Medtronic PLC
Headquarters: 710 Medtronic Parkway, Minneapolis, Minnesota, 55432-5604, USA
Form of Shares: Registered Share
Transferability and Limitations: According to the articles of incorporation of Medtronic PLC
Financial Statement: Available under www.medtronic.com

Merit Medical Systems Inc
Headquarters: 1600 W Merit Pkwy, SOUTH JORDAN, UT, 84095-2416, United States
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Merit Medical Systems Inc
Financial Statement: Available under www.merit.com

Mirati Therapeutics Inc
Headquarters: 3545 Cray Court, SAN DIEGO, CA, 92121, United States
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Mirati Therapeutics Inc
Financial Statement: Available under www.mirati.com

Molina Healthcare Inc
Headquarters: 200 Oceangate, Suite 100, LONG BEACH, CA, 90802-4317, United States
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Molina Healthcare Inc
Financial Statement: Available under www.molinacares.com

NN Group N.V.
Headquarters: Schenkkade 65, 'S-GRAVENHAGE, 2595 AS, Netherlands
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of NN Group N.V.
Financial Statement: Available under www.nn-group.com

Novo Nordisk A/S -B-
Headquarters: Novo Alle 1, BAGSVAERD, 2880, Denmark
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Novo Nordisk A/S -B-
Financial Statement: Available under www.novonordisk.com

Phoenix Group Holdings PLC
Headquarters: 1 Wythall Green Way, Wythall Green, BIRMINGHAM, B47 6WG. United Kingdom
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Phoenix Group Holdings PLC
Financial Statement: Available under www.thephoenixgroup.com

Primerica Inc
Headquarters: 1 Primerica Pkwy, DULUTH, GA, 30099-4000, United States
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Primerica Inc
Financial Statement: Available under www.primerica.com

Principal Financial Group Inc
Headquarters: 711 High St, DES MOINES, IA, 50392-0300, United States
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Principal Financial Group Inc
Financial Statement: Available under www.principal.com

Quest Diagnostics Inc
Headquarters: 500 Plaza Dr, SECAUCUS, NJ, 07094-3619, United States
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Quest Diagnostics Inc
Financial Statement: Available under www.questdiagnostics.com

R1 RCM Inc
Headquarters: 401 N Michigan Ave Ste 2700, CHICAGO, IL, 60611-4217, United States
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of R1 RCM Inc
Financial Statement: Available under www.r1rcm.com

Roche Holding AG
Headquarters: Grenzacherstrasse 124, 4070 Basel, Schweiz
Form of Shares: Dividend right certificate
Transferability and Limitations: According to the articles of incorporation of Roche Holding AG
Financial Statement: Available under www.roche.com

Shanghai Fosun Pharmaceutical (Group) Co Ltd
Headquarters: Building A, No. 1289 Yishan Road, SHANGHAI, SHA, 200233, China
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Shanghai Fosun Pharmaceutical (Group) Co Ltd
Financial Statement: Available under www.fosunpharma.com

ShockWave Medical Inc
Headquarters: 5403 Betsy Ross Dr, SANTA CLARA, CA, 95054-1162, United States
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of ShockWave Medical Inc
Financial Statement: Available under www.shockwavemedical.com

Storebrand ASA
Headquarters: Professor Kohts vei 9, LYSAKER, 1366, Norway
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Storebrand ASA
Financial Statement: Available under www.storebrand.no

Swiss Life Holding AG
Headquarters: General-Guisan-Quai 40, 8022 Zürich, Schweiz
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Swiss Life Holding AG
Financial Statement: Available under www.swisslife.com

SYNLAB AG
Headquarters: Moosacher Strasse 88, MUENCHEN, 80809, Germany
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of SYNLAB AG
Financial Statement: Available under www.ag.synlab.com

T&D Holdings Inc
Headquarters: Tokyo Nihombashi Tower, 2-7-1, Nihombashi, CHUO-KU, TKY, 103-6031, Japan
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of T&D Holdings Inc
Financial Statement: Available under www.td-holdings.co.jp

UnitedHealth Group Inc.
Headquarters: UnitedHealth Group Inc., 9900 Bren Road Est, UnitedHealth Group Center, Minnetonka, MN 55343, United States
Form of Shares: Registered Share
Transferability and Limitations: According to the articles of incorporation of UnitedHealth Group Inc.
Financial Statement: Available under www.unitedhealthgroup.com

Ventas Inc
Headquarters: 353 N Clark St Ste 3300, CHICAGO, IL, 60654-4708, United States
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Ventas Inc
Financial Statement: Available under www.ventasreit.com

Welltower Inc
Headquarters: 4500 Dorr St, TOLEDO, OH, 43615-4040, United States
Form of Shares: Registered share
Transferability and Limitations: According to the articles of incorporation of Welltower Inc
Financial Statement: Available under www.welltower.com/

Information on the past performance of the Underlying(s) can be obtained for each of the Underlying(s) on the website(s) of the respective exchange, of the Issuer or the Fund Manager. Past performance is no indication for future performance.